BAX Baxter InternationalcompanySEC Filings & Insider Trading Activity 2026
Latest Baxter International (BAX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 12, 2026, a 10-Q quarterly report filed on November 4, 2025, an 8-K current report filed on April 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Baxter International (BAX) (SEC CIK 10456), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: diversified healthcare products including IV solutions, infusion systems, parenteral nutrition, surgical and respiratory devices
- • New segment structure: three reportable segments as of Q3 2023 — Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals
Risk Factors
- • FDA warning letters dated 07/25/2023 and prior, highlighting regulatory compliance risks impacting product approvals and operations
- • Exposure to global economic conditions and inflation adversely affecting operations with no mitigation timeline specified
Management Discussion & Analysis
- • Kidney Care business sold for $3.80B cash, net after-tax proceeds approx. $3.3B completed Jan 31, 2025
- • Legacy indebtedness of $3.81B repaid in 2025, excluding $2.00B repaid from new notes offering
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • No material changes in risk factors from 2024 Annual Report
- • Continued exposure to regulatory approval delays impacting product launches
Management Discussion & Analysis
- • Revenue $2.835B Q3 2025 vs $2.699B Q3 2024; Medical Products & Therapies down 1%, Healthcare Systems & Technologies up 3%, Pharmaceuticals up 7% YoY
- • Operating margin by segment Q3 2025: Medical Products & Therapies 20.5% vs 20.0% YoY, Healthcare Systems & Technologies 13.5% vs 18.1%, Pharmaceuticals 8.9% vs 9.9%
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Disclosure clarifies 8-K content not filed under Section 18 of Exchange Act
- • Limits liability and legal implications for the company regarding this disclosure
Item 7.01: Regulation FD Disclosure
- • Baxter filed a Reg FD disclosure (Item 7.01), meaning material non-public information is being simultaneously released to all investors
- • Filing explicitly structured as "not filed" under Exchange Act Section 18 — limits shareholder litigation liability for the disclosed content
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • CFO Joel Grade out effective March 16, 2026; transitions to advisory role through April 30, 2026 with involuntary-termination severance under Executive Severance Plan
- • Anita Zielinski, SVP & Chief Accounting Officer, named interim CFO while permanent search underway — dual-role adds execution risk during ongoing restructuring
Annual Reports Archive10-K
AI-powered analysis of Baxter International (BAX) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Baxter International (BAX) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Baxter International (BAX) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $15.1B | $14.8B | $10.6B | $11.2B |
| Gross Profit | $5.4B | $5.0B | $4.0B | $3.4B |
| Operating Income | — | $390.0M | $14.0M | -$308.0M |
| Net Income | — | $2.7B | -$649.0M | -$957.0M |
| Gross Margin | 35.7% | 33.6% | 37.5% | 30.1% |
| Op. Margin | — | 2.6% | 0.1% | -2.7% |
| Net Margin | — | 17.9% | -6.1% | -8.5% |
| Balance Sheet | ||||
| Total Assets | — | $28.3B | $25.8B | $20.1B |
| Equity | — | $8.4B | $7.0B | $6.1B |
| ROE | — | 31.6% | -9.3% | -15.6% |
Source: XBRL financial data from Baxter International (BAX) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 30, 2026 | — | — | — |
8-K | Mar 19, 2026 | — | Analysis | — |
8-K | Mar 16, 2026 | — | Analysis | — |
8-K | Feb 12, 2026 | — | — | |
10-K | Feb 12, 2026 | Dec 31, 2025 | Analysis | |
8-K | Dec 22, 2025 | — | — | |
8-K | Dec 4, 2025 | — | — | |
8-K | Nov 25, 2025 | — | — | |
10-Q | Nov 4, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Feb 21, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 12, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | — | |
10-Q | May 2, 2024 | Mar 31, 2024 | — | |
10-K | Feb 8, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 2, 2023 | Sep 30, 2023 | — | |
10-Q | Jul 27, 2023 | Jun 30, 2023 | — | |
10-Q | Apr 27, 2023 | Mar 31, 2023 | — | |
10-K | Feb 9, 2023 | Dec 31, 2022 | — | |
10-Q | Oct 27, 2022 | Sep 30, 2022 | — | |
10-Q | Jul 28, 2022 | Jun 30, 2022 | — | |
10-Q | Apr 28, 2022 | Mar 31, 2022 | — | |
10-K | Feb 23, 2022 | Dec 31, 2021 | — | |
10-Q | Oct 28, 2021 | Sep 30, 2021 | — |
Frequently Asked Questions
What are the latest BAX SEC filings in 2026?
Baxter International (BAX) has filed a 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did BAX file its most recent 10-K annual report?
Baxter International (BAX) filed its most recent 10-K annual report on February 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view BAX 10-Q quarterly reports?
Baxter International (BAX)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every BAX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has BAX filed recently?
Baxter International (BAX)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find BAX insider trading activity (Form 4)?
SignalX aggregates every BAX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does BAX file with the SEC?
Baxter International (BAX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new BAX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Baxter International (BAX).
What is BAX's SEC CIK number?
Baxter International (BAX)'s SEC CIK (Central Index Key) number is 10456. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 10456 to look up all BAX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find BAX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Baxter International (BAX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Baxter International SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 48+ filings.